This trial is testing a new cancer drug to see if it is safe and effective.
3 Primary · 28 Secondary · Reporting Duration: Up to 4 years
Awards & Highlights
5 Treatment Groups
Part 2C: BMS-986288 in combination with Nivolumab and Regorafenib
1 of 5
Arm A: BMS-986288 Monotherapy
1 of 5
Arm B: BMS-986288 in combination with Nivolumab
1 of 5
Arm B BMS-986288 in combination with Nivolumab
1 of 5
Arm A BMS-986288
1 of 5
494 Total Participants · 5 Treatment Groups
Primary Treatment: BMS-986288 · No Placebo Group · Phase 1 & 2
Who is running the clinical trial?
Age 18+ · All Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What is the current enrollment rate for this trial?
"To carry out the trial, Bristol-Myers Squibb needs to recruit 344 eligible individuals. These participants will be coming from Local Institution - 0006 in Saint Louis and Washington University located in Hackensack." - Anonymous Online Contributor
Is this research unprecedented in its scope and methodology?
"Since 2012, the development of BMS-986288 has been rigorous and far reaching. Initially sponsored by Ono Pharmaceutical Co. Ltd., its initial trial attracted 659 participants in 2012; this led to Phase 1 & 2 approval from governing bodies. Nowadays, there are 718 studies across 2356 cities spread out over 49 nations tracking outcomes for BMS-986288." - Anonymous Online Contributor
Are there any opportunities for participation in this research trial?
"The documentation on clinicaltrials.gov verifies that recruitment for this trial is still open, having been first published on the 6th of September 2019 and last modified during October 19th 2022." - Anonymous Online Contributor
In what areas can participants access this clinical trial?
"This medical trial is being run in multiple different locations, including Local Institution - 0006 in Saint Louis, Missouri, Washington University in Hackensack, New Jersey and the Hackensack University Medical Center of Baltimore, Maryland." - Anonymous Online Contributor
Has the efficacy of BMS-986288 been previously assessed in any other clinical trials?
"BMS-986288 was initially investigated in 2012 at a nearby medical facility. Since then, there have been 252 trials completed and 718 ongoing tests around the world. Most of these are happening in Saint Louis, Missouri." - Anonymous Online Contributor
What ailments is BMS-986288 typically prescribed to treat?
"BMS-986288 is regularly prescribed for the management of malignant neoplasms. Additionally, it has been shown to be efficacious in cases where patients have unresectable melanoma, squamous cell carcinoma, or metastatic esophageal adenocarcinoma." - Anonymous Online Contributor